Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Enhancer hijacking in acute myeloid leukemia

Recurrent deletions in cancer genomes overlap with the chromosomal locations of tumor-suppressor genes. Knudson's two-hit hypothesis has successfully guided cancer biologists for the past fifty years in the identification of such tumor-suppressor genes. However, in many cases monoallelic loss can only explain haploinsufficiency of tumor-suppressor genes. Preliminary work in the division indicates that altered chromosome topology and epigenetic gene regulation can also affected by deletions, resulting in the activation of oncogenes located outside of the deleted segment.

We aim to establish a novel paradigm in interpreting (epi)genomic data in cancer. We hypothesize that oncogene activation, in concert with haploinsufficient tumor-suppressor genes, deregulated because of a single genetic event, could lead to the discovery of novel intertwined oncogenic pathways.

Using acute myeloid leukemia as a model, we aim:

  • to reveal oncogene activation through novel molecular pathways in cases carrying deletions of 5q and 7q by molecular sequencing-based profiling and to validate the requirement of the novel oncogene(s) for leukemic growth.
  • to determine the molecular mechanisms resulting from oncogene overexpression and to test the accelerated tumorigenesis dependent on haploinsufficient tumor suppressor genes.
  • to determine the contribution of oncogene activation through structural variation in combination with haploinsufficiency in a pan-cancer setting.

to top
powered by webEdition CMS